Lisbon – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 17 Jul 2026 04:07:08 +0000 en-US hourly 1 https://wordpress.org/?v=7.0.2 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Lisbon – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis: Phase 2/3 Open‑Label and Randomized Placebo‑Controlled Study https://clinicaltrials.eu/trial/efficacy-and-safety-of-pegcetacoplan-in-adults-and-adolescents-with-focal-segmental-glomerulosclerosis-phase-2-3-open-label-and-randomized-placebo-controlled-study/ Thu, 16 Jul 2026 04:05:35 +0000 https://clinicaltrials.eu/trial/efficacy-and-safety-of-pegcetacoplan-in-adults-and-adolescents-with-focal-segmental-glomerulosclerosis-phase-2-3-open-label-and-randomized-placebo-controlled-study/ Focal segmental glomerulosclerosis is a rare kidney condition in which small parts of the filtering units become scarred, leading to leakage of protein into the urine. This leakage, called proteinuria, can be measured by the amount of protein relative to creatinine in a urine sample. The study evaluates the investigational drug pegcetacoplan, which is given by a subcutaneous injection, meaning it is administered under the skin.

The purpose of the study is to determine whether twice‑weekly dosing of the drug can lower protein loss in the urine compared with placebo. Participants will first receive the active medication in an open‑label phase, followed by a randomized, double‑blind phase where some receive the drug and others receive the placebo, with regular monitoring of kidney function and safety.

Throughout the trial, participants will have periodic clinic visits where urine samples are collected to calculate the urine protein to creatinine ratio and the urine albumin to creatinine ratio, both of which indicate the level of protein leakage. Blood tests will also be performed to assess the estimated Glomerular Filtration Rate, a standard measure of how well the kidneys are filtering waste. The study continues over several months to observe changes in these measurements and to ensure the treatment is safe.

]]> A Study to Assess Safety and Efficacy of Surzetoclax Alone or with Etentamig in Adults with Relapsed or Refractory Multiple Myeloma https://clinicaltrials.eu/trial/a-study-to-assess-safety-and-efficacy-of-surzetoclax-alone-or-with-etentamig-in-adults-with-relapsed-or-refractory-multiple-myeloma/ Wed, 15 Jul 2026 04:04:57 +0000 https://clinicaltrials.eu/trial/a-study-to-assess-safety-and-efficacy-of-surzetoclax-alone-or-with-etentamig-in-adults-with-relapsed-or-refractory-multiple-myeloma/ The study focuses on Multiple Myeloma, a blood cancer that starts in the cells that produce antibodies. It tests an oral tablet called Surzetoclax, which blocks a protein that helps cancer cells survive, and a medicine given through a vein called Etentamig. Both drugs may be used alone or together with other standard treatments that are usually given under the skin or by mouth.

The purpose is to find out how safe the medicines are and whether they can lower the activity of the cancer. Adults whose disease has returned after earlier therapy (relapsed) or does not respond to usual medicines (refractory) will receive the study drugs for several treatment cycles. Participants will have regular doctor visits, blood tests, and scans to watch for side effects and to see if the cancer shrinks. Terms like “biomarker‑selected” mean that a laboratory test is used to choose patients whose cancer has a specific characteristic; “dose limiting toxicity” describes side effects that stop the dose from being increased; and “overall response rate” is the percentage of patients whose cancer gets smaller or disappears.

]]> Safety, Pharmacokinetics, and Exploratory Efficacy of BI 1015550 and Nerandomilast in Children and Adolescents Aged 2‑17 Years With Fibrosing Interstitial Lung Disease https://clinicaltrials.eu/trial/safety-pharmacokinetics-and-exploratory-efficacy-of-bi-1015550-and-nerandomilast-in-children-and-adolescents-aged-2-17-years-with-fibrosing-interstitial-lung-disease/ Thu, 09 Jul 2026 04:04:39 +0000 https://clinicaltrials.eu/trial/safety-pharmacokinetics-and-exploratory-efficacy-of-bi-1015550-and-nerandomilast-in-children-and-adolescents-aged-2-17-years-with-fibrosing-interstitial-lung-disease/ The trial looks at children and adolescents with fibrosing interstitial lung disease, a condition where scar tissue builds up in the lungs and makes breathing difficult. The medication being tested is called nerandomilast, given as a film‑coated tablet taken by mouth. A group will receive the active drug while another group will receive a placebo, which looks the same but contains no active ingredient. The main aim is to find out how the drug is handled by the body and whether it is safe for this age group.

Participants will be divided by age. Those aged 6 to under 18 will be part of a double‑blind phase where neither the participants nor the doctors know who receives the drug or the placebo, followed by an open‑label phase where everyone receives the active medication. Children younger than 6 will start directly with the active drug in an open‑label part. Over the course of the study, researchers will watch for side effects and will measure simple health indicators such as oxygen saturation (SpO2), lung capacity measured as FVC, and the distance walked in six minutes (6‑min walk distance), as well as growth and quality‑of‑life questionnaires.

]]> Phase 2/3 study of telisotuzumab adizutecan with drug combination versus standard care in adults with first‑line metastatic pancreatic ductal adenocarcinoma https://clinicaltrials.eu/trial/phase-2-3-study-of-telisotuzumab-adizutecan-with-drug-combination-versus-standard-care-in-adults-with-first-line-metastatic-pancreatic-ductal-adenocarcinoma/ Wed, 08 Jul 2026 04:04:47 +0000 https://clinicaltrials.eu/trial/phase-2-3-study-of-telisotuzumab-adizutecan-with-drug-combination-versus-standard-care-in-adults-with-first-line-metastatic-pancreatic-ductal-adenocarcinoma/ The condition being studied is metastatic pancreatic ductal adenocarcinoma, an advanced form of pancreatic cancer that has spread to other parts of the body. The experimental treatment combines an intravenous antibody called Telisotuzumab adizutecan with a chemotherapy regimen known as FOLFOX, which contains fluorouracil, calcium folinate, and oxaliplatin. For comparison, participants may receive the usual standard of care that can include irinotecan together with the same chemotherapy drugs.

The main goal of the trial is to determine whether the new combination is safe and works better than current therapies. Participants will receive the assigned medicines by IV infusion in repeated cycles, with regular hospital visits for the infusions and for medical checks. Throughout the study, doctors will look for signs that tumors shrink, known as objective response, and will track how long patients live, referred to as overall survival.

After random assignment to either the experimental group or the standard‑care group, treatment continues for several weeks while imaging scans, blood tests, and questionnaires are used to assess tumor size, side effects, and quality of life. The study also measures how long the disease stays under control without getting worse, called progression‑free survival, before participants are followed for long‑term survival outcomes.

]]> Study Comparing Axicabtagene Ciloleucel and Standard Treatment for Adults with High-Risk Large B-Cell Lymphoma https://clinicaltrials.eu/trial/study-comparing-axicabtagene-ciloleucel-and-standard-treatment-for-adults-with-high-risk-large-b-cell-lymphoma/ Fri, 03 Jul 2026 04:02:41 +0000 https://clinicaltrials.eu/trial/study-comparing-axicabtagene-ciloleucel-and-standard-treatment-for-adults-with-high-risk-large-b-cell-lymphoma/ This clinical trial is focused on studying a type of cancer called high-risk large B-cell lymphoma, which includes subtypes like diffuse large B-cell lymphoma and high-grade B-cell lymphoma. The trial aims to compare the effectiveness of a new treatment called axicabtagene ciloleucel with the standard treatments currently used for this condition. Axicabtagene ciloleucel is a type of therapy that involves modifying a patient’s own immune cells to better fight cancer.

Participants in the study will receive either axicabtagene ciloleucel or standard treatments, which may include medications such as prednisone, cyclophosphamide, dexamethasone, vincristine, tocilizumab, doxorubicin, diphenhydramine, rituximab, etoposide, mesna, methylprednisolone, fludarabine, and other analgesics and antipyretics. Some participants may receive a placebo. The study will monitor how well the treatments work by looking at how long participants live without the cancer getting worse and other health outcomes.

The trial will take place over a period of time, during which participants will receive their assigned treatment and have regular check-ups to monitor their health and the progress of the treatment. The goal is to determine which treatment is more effective in improving the lives of people with high-risk large B-cell lymphoma. Participants will be closely monitored for any side effects or changes in their condition throughout the study.

]]> Safety and Tolerability of Intrathecal ION337 in Patients with Dravet Syndrome https://clinicaltrials.eu/trial/safety-and-tolerability-of-intrathecal-ion337-in-patients-with-dravet-syndrome/ Thu, 02 Jul 2026 04:04:16 +0000 https://clinicaltrials.eu/trial/safety-and-tolerability-of-intrathecal-ion337-in-patients-with-dravet-syndrome/ The study involves patients with Dravet Syndrome, a rare genetic condition that causes frequent and severe seizures. The investigational drug being tested is called ION337, which is given by an intrathecal injection, meaning the medicine is placed directly into the fluid surrounding the spinal cord. The purpose of the study is to evaluate the safety and tolerability of ION337 in this population. Safety checks include monitoring for any side effects, changes in blood tests, heart rhythm, and overall health assessments.

Participants will first receive a single low dose of the medication, followed by a period of observation. After this initial phase, they may receive multiple increasing doses over several weeks, with regular clinic visits to check how the drug is processed in the body and to record any changes in seizure frequency. Samples of the fluid around the brain and spinal cord (CSF) and blood are taken to understand how the drug moves through the body, and seizure counts are recorded to see if there is any improvement. Throughout the study, doctors closely watch for any adverse events and adjust the plan as needed.

]]> Long‑Term Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease https://clinicaltrials.eu/trial/long-term-safety-and-tolerability-of-treprostinil-palmitil-inhalation-powder-in-patients-with-pulmonary-hypertension-associated-with-interstitial-lung-disease/ Thu, 02 Jul 2026 04:04:15 +0000 https://clinicaltrials.eu/trial/long-term-safety-and-tolerability-of-treprostinil-palmitil-inhalation-powder-in-patients-with-pulmonary-hypertension-associated-with-interstitial-lung-disease/ The study focuses on Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD), a condition in which high blood pressure in the lungs occurs together with scarring of lung tissue, leading to shortness of breath and reduced ability to exercise. The treatment being examined is an inhaled medication called Treprostinil Palmitil Inhalation Powder, also referred to by the code name TPIP, which is taken as a dry‑powder capsule that is breathed in.

The aim of the study is to evaluate the safety and tolerability of long‑term use of this medication. Participants who have previously taken part in an earlier trial will continue to receive the inhaled powder and will be followed for up to two years. During this time they will attend regular clinic visits where simple checks such as blood tests, heart rhythm monitoring (ECG), measurement of oxygen use, and basic physical examinations are performed. The study also includes a group receiving placebo for comparison.

Throughout the study, participants will undergo a short walking test (6MWD) to see how far they can walk in six minutes, and lung function tests that measure the amount of air they can force out (FVC) and the speed of airflow (FEV1). Blood samples will be taken to check levels of a heart‑stress marker (NT-proBNP). These assessments help researchers understand how the medication affects breathing ability, heart strain, and overall health over the long term.

]]> Study of Mirikizumab for Children and Teens with Moderate-to-Severe Ulcerative Colitis or Crohn’s Disease https://clinicaltrials.eu/trial/study-of-mirikizumab-for-children-and-teens-with-moderate-to-severe-ulcerative-colitis-or-crohns-disease/ Thu, 02 Jul 2026 04:02:45 +0000 https://clinicaltrials.eu/trial/study-of-mirikizumab-for-children-and-teens-with-moderate-to-severe-ulcerative-colitis-or-crohns-disease/ This clinical trial is focused on studying the effects of a medication called Mirikizumab on children and adolescents who have either Ulcerative Colitis or Crohn’s Disease. These are types of Inflammatory Bowel Diseases, which cause inflammation in the digestive tract, leading to symptoms like abdominal pain, diarrhea, and fatigue. The medication being tested, Mirikizumab, is given as a solution for injection and is being evaluated for its long-term safety and effectiveness in managing these conditions.

The purpose of the study is to assess how well Mirikizumab works in treating these diseases over an extended period. Participants in the study will receive the medication and be monitored to see how their symptoms change over time. The study will look at whether the medication helps achieve clinical remission, which means a significant reduction or disappearance of symptoms, in participants with either Ulcerative Colitis or Crohn’s Disease.

Throughout the study, participants will receive regular injections of Mirikizumab and will have follow-up visits to track their progress. The study aims to provide valuable information on the long-term use of Mirikizumab in young patients with these chronic conditions, helping to determine its potential benefits and any side effects that may occur during treatment.

]]> Study of telisotuzumab adizutecan plus drug combination in adults with refractory metastatic colorectal cancer https://clinicaltrials.eu/trial/study-of-telisotuzumab-adizutecan-plus-drug-combination-in-adults-with-refractory-metastatic-colorectal-cancer/ Wed, 01 Jul 2026 04:04:09 +0000 https://clinicaltrials.eu/trial/study-of-telisotuzumab-adizutecan-plus-drug-combination-in-adults-with-refractory-metastatic-colorectal-cancer/ The study focuses on Colorectal Cancer, a type of cancer that starts in the colon or rectum and can spread to other parts of the body (metastatic). Participants have disease that no longer responds to standard treatments (refractory). The experimental group receives an intravenous (IV) infusion of telisotuzumab adizutecan (code name ABBV-400) together with IV bevacizumab. The comparison group receives the usual care, which includes oral tablets of trifluridine and tipiracil taken by mouth, plus IV bevacizumab. The purpose of the study is to determine whether the new combination can shrink tumors and help patients live longer than the standard therapy.

Participants will receive their assigned medicines on a regular schedule, with IV infusions given at the clinic and oral tablets taken at home. Throughout the study, doctors will perform routine checks, imaging scans, and questionnaires to monitor tumor size, side effects, and overall health. The trial continues until a predefined number of assessments are completed or until a participant stops treatment, after which follow‑up visits assess long‑term outcomes.

]]> Study of LY4268989 adipic acid in adults with moderately to severely active ulcerative colitis https://clinicaltrials.eu/trial/study-of-ly4268989-adipic-acid-in-adults-with-moderately-to-severely-active-ulcerative-colitis/ Wed, 01 Jul 2026 04:04:09 +0000 https://clinicaltrials.eu/trial/study-of-ly4268989-adipic-acid-in-adults-with-moderately-to-severely-active-ulcerative-colitis/ The study focuses on adults who have Ulcerative Colitis that is moderately to severely active, meaning the colon is inflamed and causes frequent diarrhea, abdominal pain, and blood in the stool. The investigational medicine being tested is identified by the code name LY4268989, which is taken as an oral tablet. For comparison, participants may receive a matching placebo, which looks the same but does not contain the active drug.

The main goal of the trial is to find out whether LY4268989 can bring more participants into clinical remission—periods when symptoms are absent or very mild—than the placebo during the first 10 weeks and to see if the benefit continues through a longer, 52‑week maintenance phase for those who respond early. Participants will start by taking the study tablets daily for about ten weeks (the induction phase). If they show improvement, they may continue the same treatment for up to a year (the maintenance phase), with regular visits to check how they are doing.

During the study, doctors will use a scoring system called the Modified Mayo Score to decide whether a person has reached remission; this score looks at stool frequency, bleeding, endoscopic findings, and overall health. “Induction” refers to the initial treatment period aimed at quickly reducing inflammation, while “maintenance” means the ongoing treatment intended to keep the disease under control. Participants will have routine check‑ups, blood tests, and questionnaires to monitor safety and how well the medication works.

]]> Study on Fenebrutinib and Teriflunomide for Adults with Relapsing Multiple Sclerosis https://clinicaltrials.eu/trial/study-on-fenebrutinib-and-teriflunomide-for-adults-with-relapsing-multiple-sclerosis/ Wed, 01 Jul 2026 04:03:23 +0000 https://clinicaltrials.eu/trial/study-on-fenebrutinib-and-teriflunomide-for-adults-with-relapsing-multiple-sclerosis/ This clinical trial is focused on studying a condition known as Relapsing Multiple Sclerosis (RMS). RMS is a type of multiple sclerosis where patients experience episodes of new or worsening symptoms, known as relapses, followed by periods of recovery. The study aims to evaluate the effectiveness and safety of a medication called Fenebrutinib compared to another medication called Teriflunomide. Fenebrutinib is taken in the form of film-coated tablets and is being tested to see how well it works in reducing the frequency of relapses in patients with RMS.

Participants in the study will be randomly assigned to receive either Fenebrutinib, Teriflunomide, or a placebo. A placebo is a substance with no active medication, used to compare the effects of the actual drugs being tested. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving which treatment, to ensure unbiased results. The trial will last for a period of time during which participants will take the medication orally, and their health will be monitored regularly to assess the impact of the treatment on their condition.

The main goal of the study is to determine how well Fenebrutinib works in reducing the annualized relapse rate, which is the average number of relapses a patient experiences in a year. Additionally, the study will look at other factors such as changes in brain volume, the number of new or enlarging lesions detected by MRI scans, and any side effects experienced by participants. This research is important for understanding the potential benefits and risks of Fenebrutinib as a treatment option for people living with RMS.

]]> Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis https://clinicaltrials.eu/trial/study-on-clazakizumab-for-heart-disease-in-adults-with-end-stage-kidney-disease-on-dialysis/ Tue, 30 Jun 2026 04:02:44 +0000 https://clinicaltrials.eu/trial/study-on-clazakizumab-for-heart-disease-in-adults-with-end-stage-kidney-disease-on-dialysis/ This clinical trial is focused on studying the effects of a medication called Clazakizumab in patients with End Stage Kidney Disease (ESKD) who are undergoing dialysis. ESKD is a condition where the kidneys can no longer function properly, and dialysis is a treatment that helps to remove waste and excess fluid from the blood. The study aims to explore how different doses of Clazakizumab, given as an injection, can help reduce inflammation in the body, which is measured by a substance in the blood called high-sensitivity C-reactive protein (hs-CRP). Inflammation is a common issue in patients with ESKD and can lead to other health problems, including heart disease.

The trial will compare the effects of Clazakizumab with a placebo, which is a substance that looks like the medication but does not contain the active ingredient. The study will also use a saline solution, which is a simple saltwater solution, as part of the trial process. The purpose of the study is to determine the best dose of Clazakizumab that can effectively reduce inflammation and to assess its safety in patients with ESKD. Participants will receive the medication or placebo through an intravenous injection, which means it is given directly into a vein.

Throughout the study, researchers will monitor the participants’ health and track any changes in their condition. The study will also look at the impact of Clazakizumab on cardiovascular health, which refers to the health of the heart and blood vessels. This is important because patients with ESKD are at a higher risk of developing heart-related issues. The trial is designed to provide valuable information on how Clazakizumab can help manage inflammation and improve overall health outcomes for patients with ESKD undergoing dialysis.

]]> A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis https://clinicaltrials.eu/trial/phase-3-randomized-study-of-orelabrutinib-in-patients-with-non-active-secondary-progressive-multiple-sclerosis/ Fri, 26 Jun 2026 04:05:25 +0000 https://clinicaltrials.eu/trial/phase-3-randomized-study-of-orelabrutinib-in-patients-with-non-active-secondary-progressive-multiple-sclerosis/ The study focuses on Non-active Secondary Progressive Multiple Sclerosis, a form of multiple sclerosis where the disease has become steadily worse without new relapses. The investigational medication being tested is an oral tablet called Orelabrutinib, which is taken by mouth, and it will be compared with an identical looking placebo tablet.

The purpose of the study is to evaluate whether Orelabrutinib can delay the worsening of disability compared with placebo. Participants will receive the assigned tablet each day for several years and will attend regular clinic visits where their ability to perform everyday tasks is checked and brain scans using MRI are performed to look for new lesions. The study will track how long it takes before a confirmed increase in disability occurs and will record any safety concerns throughout the trial.

]]> Study on the Effects of Fidrisertib for Treating Fibrodysplasia Ossificans Progressiva in Children and Adults https://clinicaltrials.eu/trial/study-on-the-effects-of-fidrisertib-for-treating-fibrodysplasia-ossificans-progressiva-in-children-and-adults/ Fri, 26 Jun 2026 04:04:13 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-fidrisertib-for-treating-fibrodysplasia-ossificans-progressiva-in-children-and-adults/ This clinical trial is focused on studying a rare condition called Fibrodysplasia Ossificans Progressiva (FOP). FOP is a disorder where soft tissues in the body, like muscles and tendons, gradually turn into bone, leading to restricted movement. The study is testing a new treatment called fidrisertib, also known by its code name IPN60130. This treatment is being compared to a placebo to see if it can help reduce the formation of new bone in people with FOP.

The purpose of the study is to evaluate how effective and safe fidrisertib is for both children and adults with FOP. Participants in the study will take the medication in the form of a hard capsule by mouth. The study will last for a period of up to 60 days, during which participants will be monitored for any changes in their condition and any side effects they might experience. The study will use imaging techniques like computed tomography (CT) to measure changes in bone formation.

Throughout the study, participants will have regular check-ups to assess their health and the progress of their condition. The study aims to provide valuable information on whether fidrisertib can effectively slow down or stop the progression of FOP, offering hope for better management of this challenging condition. Participants will be closely monitored to ensure their safety and well-being during the trial.

]]> Centro Hospitalar de Lisoba Ocidental, E.P.E. https://clinicaltrials.eu/site/centro-hospitalar-de-lisoba-ocidental-e-p-e/ Wed, 24 Jun 2026 04:11:22 +0000 https://clinicaltrials.eu/site/centro-hospitalar-de-lisoba-ocidental-e-p-e/ Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis https://clinicaltrials.eu/trial/long-term-safety-and-tolerability-of-admilparant-in-adults-with-idiopathic-or-progressive-pulmonary-fibrosis/ Tue, 23 Jun 2026 04:12:48 +0000 https://clinicaltrials.eu/trial/long-term-safety-and-tolerability-of-admilparant-in-adults-with-idiopathic-or-progressive-pulmonary-fibrosis/ The study focuses on two lung conditions, Progressive pulmonary fibrosis and Idiopathic pulmonary fibrosis, in which scar tissue builds up in the lungs and makes breathing harder. The treatment being examined is an oral tablet called Admilparant, which belongs to a group of medicines that aim to reduce the formation of scar tissue. The tablet is taken by mouth and is designed for long‑term use.

The purpose of the study is to determine whether Admilparant can be used safely over an extended period without causing serious side effects. Participants will take the medication each day and will attend regular visits where healthcare staff will check vital signs such as blood pressure and heart rate, review simple blood tests, and perform a basic heart test known as an ECG, which records the heart’s electrical activity. Any side effects that arise will be recorded and evaluated.

The study will continue for many months to gather enough information about safety and tolerability. Throughout the study, participants will be asked to report any new symptoms or problems, and they will receive routine medical check‑ups to monitor their overall health while using the medication.

]]> Venetoclax added to fludarabine, cytarabine and gemtuzumab ozogamicin (drug combination) in children with relapsed acute myeloid leukemia https://clinicaltrials.eu/trial/venetoclax-with-drug-combination-for-children-with-relapsed-acute-myeloid-leukemia/ Thu, 18 Jun 2026 04:08:12 +0000 https://clinicaltrials.eu/trial/venetoclax-with-drug-combination-for-children-with-relapsed-acute-myeloid-leukemia/ The study looks at children whose acute myeloid leukemia has come back after treatment (called relapsed). The medicines being tested are a pill called Venetoclax taken by mouth, and three other medicines given by injection: fludarabine, cytarabine, and gemtuzumab ozogamicin. These drugs are used together to try to kill leukemia cells.

The goal of the trial is to find out whether adding Venetoclax to the standard three‑drug mix can improve overall survival, which means living longer after the treatment starts.

In this phase 3 study, children are placed by chance into one of two groups: one group receives the three standard drugs, and the other group receives the same three drugs plus the oral Venetoclax. Treatment is given in cycles over several weeks, and the children are checked regularly to see how they are doing and to record any side effects. The study follows each participant for a period of time to see how long they live and how they feel.

]]> A Phase 2b/3 Randomized Double‑Blind Study of Ataciguat to Slow Disease Progression in Adults with Moderate Calcific Aortic Valve Stenosis https://clinicaltrials.eu/trial/study-of-ataciguat-to-slow-progression-of-moderate-calcific-aortic-valve-stenosis-in-adults/ Wed, 17 Jun 2026 04:03:04 +0000 https://clinicaltrials.eu/trial/study-of-ataciguat-to-slow-progression-of-moderate-calcific-aortic-valve-stenosis-in-adults/ People with Moderate Calcific Aortic Valve Stenosis have a heart valve that becomes thick and stiff, making it harder for blood to flow from the heart to the rest of the body. The study is testing an oral medication called Ataciguat, which is taken as a capsule each day, and comparing it with a placebo that looks the same but contains no active drug.

The purpose of the study is to find out whether the medication can slow the narrowing of the valve and improve the ability to exercise. Participants are randomly assigned to receive either the study drug or the placebo for about a year, with regular clinic visits. During the study, doctors will use an echocardiogram (an ultrasound picture of the heart) to see how big the valve opening is, and a peak VO2 test, measured during a CPET (a breathing and heart test done while exercising), to check how well the body uses oxygen. A CT scan (a detailed X‑ray picture) will also be performed to look at calcium buildup in the valve. If the valve becomes too narrow, doctors may discuss procedures such as TAVR (a catheter‑based valve replacement) or SAVR (surgical valve replacement).

Throughout the trial, participants will be monitored for any side effects, and safety checks will be done at each visit. The study team will collect information about health changes and any additional treatments needed, while keeping participants’ personal information confidential.

]]> Study on the Effectiveness and Safety of Sonelokimab for Adults with Moderate to Severe Hidradenitis Suppurativa https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-sonelokimab-for-adults-with-moderate-to-severe-hidradenitis-suppurativa/ Fri, 05 Jun 2026 10:52:45 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-sonelokimab-for-adults-with-moderate-to-severe-hidradenitis-suppurativa/ This clinical trial is focused on studying a skin condition called hidradenitis suppurativa, which is a chronic inflammatory disease that causes painful lumps under the skin, often in areas like the armpits and groin. The trial will evaluate a treatment called sonelokimab, which is given as a subcutaneous injection, meaning it is injected under the skin. Sonelokimab is a type of medication known as a nanobody, which works by inhibiting proteins called IL-17A and IL-17F that are involved in inflammation. The study will compare the effects of sonelokimab with a placebo, which is a sterile solution that looks like the medication but does not contain any active ingredients.

The purpose of the study is to assess how effective and safe sonelokimab is for adults with moderate to severe hidradenitis suppurativa. Participants in the study will receive either sonelokimab or a placebo over a period of 16 weeks. During this time, researchers will monitor the participants to see if there is a 75% improvement in their condition, which is measured by a specific score called the Hidradenitis Suppurativa Clinical Response (HiSCR) score. The study will also track any side effects or adverse events that occur during the treatment period.

Throughout the study, participants will undergo regular check-ups, including physical examinations and laboratory tests, to ensure their safety and to gather data on the treatment’s effects. The trial aims to provide valuable information on whether sonelokimab can be a beneficial treatment option for those suffering from hidradenitis suppurativa, potentially improving their quality of life by reducing the severity of their symptoms.

]]> Study Comparing Nemtabrutinib, Ibrutinib, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma https://clinicaltrials.eu/trial/study-comparing-nemtabrutinib-ibrutinib-and-acalabrutinib-for-patients-with-untreated-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-2/ Fri, 05 Jun 2026 10:51:16 +0000 https://clinicaltrials.eu/trial/study-comparing-nemtabrutinib-ibrutinib-and-acalabrutinib-for-patients-with-untreated-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-2/ This clinical trial is focused on studying two diseases: Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). These are types of blood cancers that affect the white blood cells. The study will compare the effectiveness of a new treatment called Nemtabrutinib with two existing treatments, Ibrutinib and Acalabrutinib. These medications are taken orally in tablet form and are designed to help manage these conditions by targeting specific proteins in cancer cells.

The purpose of the study is to see how well Nemtabrutinib works compared to the other two treatments in people who have not yet received treatment for their CLL or SLL. Participants will be randomly assigned to receive either Nemtabrutinib or one of the other two medications chosen by the study doctor. The study will last for a period of up to 108 weeks, during which participants will take the medication daily and attend regular check-ups to monitor their health and the progress of the disease.

Throughout the study, doctors will assess how the disease responds to the treatment and how long participants remain free from disease progression. They will also monitor overall survival and any side effects experienced by participants. The study aims to provide valuable information on the effectiveness and safety of Nemtabrutinib compared to the current standard treatments for CLL and SLL.

]]> Study of Upadacitinib for Adolescents and Adults with Moderate to Severe Eczema https://clinicaltrials.eu/trial/study-of-upadacitinib-for-adolescents-and-adults-with-moderate-to-severe-eczema-2/ Fri, 05 Jun 2026 10:50:49 +0000 https://clinicaltrials.eu/trial/study-of-upadacitinib-for-adolescents-and-adults-with-moderate-to-severe-eczema-2/ This clinical trial is focused on studying the effects of a medication called Upadacitinib on individuals with moderate to severe Atopic Dermatitis, commonly known as eczema. Eczema is a condition that causes the skin to become itchy, red, and inflamed. The study involves both adolescents and adults who are experiencing significant symptoms of this skin condition. The purpose of the study is to evaluate how effective and safe Upadacitinib is for treating these symptoms. Upadacitinib is a type of medication known as a Janus kinase (Jak) 1 inhibitor, which works by blocking certain enzymes in the body that contribute to inflammation.

Participants in the study will be randomly assigned to receive either Upadacitinib or a placebo, which is a substance with no active medication. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not influenced by expectations. The study will last for a period of time, during which participants will take the medication orally in the form of a modified-release tablet. The goal is to observe any changes in the severity of eczema symptoms and overall skin condition over the course of the study.

Throughout the study, participants will be monitored for any improvements in their eczema symptoms, such as reduced itching and inflammation, as well as any potential side effects. The study aims to provide valuable information on whether Upadacitinib can be an effective treatment option for those suffering from moderate to severe eczema. By participating in this study, researchers hope to gain insights that could lead to better management and treatment options for individuals with this challenging skin condition.

]]> Study on the Effects of RO7200220 for Adults and Children with Uveitic Macular Edema https://clinicaltrials.eu/trial/study-on-the-effects-of-ro7200220-for-adults-and-children-with-uveitic-macular-edema/ Fri, 05 Jun 2026 10:50:30 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-ro7200220-for-adults-and-children-with-uveitic-macular-edema/ This clinical trial is focused on studying a condition called Uveitic Macular Edema, which is a swelling in the central part of the retina, often associated with inflammation in the eye. The study is testing a treatment called RO7200220, also known by its code name IL6-Mab. This treatment is a type of medication known as a humanised IgG2 monoclonal antibody against interleukin-6, which is designed to target and reduce inflammation. The medication is given as a solution for injection directly into the eye.

The purpose of the study is to evaluate how effective and safe this treatment is for patients with Uveitic Macular Edema. Participants in the study will receive either the actual medication or a placebo. The study will monitor changes in vision and eye health over time, with particular attention to improvements in visual clarity and reductions in retinal swelling. The study will also assess the safety of the treatment by tracking any side effects that may occur.

Throughout the study, participants will have regular check-ups to measure their vision and eye condition. The study will last for a period of up to 52 weeks, during which the effects of the treatment will be closely observed. The goal is to determine if the treatment can significantly improve vision and reduce swelling in the retina for those affected by this condition.

]]> Study on the Effectiveness and Safety of Secukinumab for Adults with Moderate to Severe Rotator Cuff Tendinopathy https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-secukinumab-for-adults-with-moderate-to-severe-rotator-cuff-tendinopathy/ Fri, 05 Jun 2026 10:50:16 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-secukinumab-for-adults-with-moderate-to-severe-rotator-cuff-tendinopathy/ This clinical trial is focused on studying the effects of a medication called secukinumab on individuals with moderate to severe rotator cuff tendinopathy. Rotator cuff tendinopathy is a condition that affects the shoulder, causing pain and difficulty in movement. The purpose of the study is to determine if secukinumab can improve shoulder symptoms better than a placebo. Secukinumab is administered as a solution for injection using a pre-filled syringe.

Participants in the study will receive either secukinumab or a placebo. The study will last for 24 weeks, during which the effects of the treatment on shoulder symptoms will be monitored. The main focus will be on changes in physical symptoms related to the shoulder, assessed at different points throughout the study. Participants will be asked to continue any existing treatments, such as non-steroidal anti-inflammatory drugs (NSAIDs) and physiotherapy, at a stable dosage and regimen.

The study will also involve monitoring the safety and tolerability of secukinumab, including any side effects or changes in laboratory results. Participants will have their progress evaluated through various assessments, including the Western Ontario Rotator Cuff Index (WORC) and the Patient-Reported Outcomes Measurement Information System (PROMIS). The study aims to provide valuable insights into the potential benefits of secukinumab for individuals with rotator cuff tendinopathy.

]]> Instituto Valenciano De Infertilidade Clinica De Reproducao Assistida Lda. https://clinicaltrials.eu/site/instituto-valenciano-de-infertilidade-clinica-de-reproducao-assistida-lda/ Tue, 02 Jun 2026 09:58:04 +0000 https://clinicaltrials.eu/site/instituto-valenciano-de-infertilidade-clinica-de-reproducao-assistida-lda/ Hospital Das Forcas Armadas https://clinicaltrials.eu/site/hospital-das-forcas-armadas/ Tue, 02 Jun 2026 09:57:49 +0000 https://clinicaltrials.eu/site/hospital-das-forcas-armadas/ Unidade Local de Saúde Lisboa Ocidental (ULSLO) https://clinicaltrials.eu/site/unidade-local-de-saude-lisboa-ocidental-ulslo/ Tue, 02 Jun 2026 09:57:45 +0000 https://clinicaltrials.eu/site/unidade-local-de-saude-lisboa-ocidental-ulslo/ Unidade Local De Saude De Sao Jose E.P.E. https://clinicaltrials.eu/site/unidade-local-de-saude-de-sao-jose-e-p-e-3/ Tue, 02 Jun 2026 09:57:36 +0000 https://clinicaltrials.eu/site/unidade-local-de-saude-de-sao-jose-e-p-e-3/ Nephrocare APDP https://clinicaltrials.eu/site/nephrocare-apdp/ Tue, 02 Jun 2026 09:57:28 +0000 https://clinicaltrials.eu/site/nephrocare-apdp/ Personal Derma – Clínica Dermatológica & Estética https://clinicaltrials.eu/site/personal-derma-clinica-dermatologica-estetica/ Tue, 02 Jun 2026 09:57:27 +0000 https://clinicaltrials.eu/site/personal-derma-clinica-dermatologica-estetica/ Centro Hospitalar Universitário Lisboa Central E.P.E. https://clinicaltrials.eu/site/centro-hospitalar-universitario-lisboa-central-e-p-e/ Tue, 02 Jun 2026 09:57:26 +0000 https://clinicaltrials.eu/site/centro-hospitalar-universitario-lisboa-central-e-p-e/ Hospital Curry Cabral_Centro Hospitalar de Lisboa Central – ULS Sao José https://clinicaltrials.eu/site/hospital-curry-cabral-centro-hospitalar-de-lisboa-central-uls-sao-jose/ Tue, 02 Jun 2026 09:57:22 +0000 https://clinicaltrials.eu/site/hospital-curry-cabral-centro-hospitalar-de-lisboa-central-uls-sao-jose/ Progesterone as an Ovulation Trigger in Women with Infertility https://clinicaltrials.eu/trial/progesterone-as-an-ovulation-trigger-in-women-with-infertility/ Tue, 02 Jun 2026 09:56:41 +0000 https://clinicaltrials.eu/trial/progesterone-as-an-ovulation-trigger-in-women-with-infertility/ This clinical trial is studying Infertility, a condition in which pregnancy does not happen after regular attempts. The treatment being used is progesterone, given as Cyclogest 400 mg óvulos by vaginal use. The purpose of the study is to see whether progesterone given late in the menstrual cycle can help start the process that leads to egg maturation, which is the normal development of an egg before it is collected.

In this study, progesterone is given at a specific time in the cycle. After treatment, the study follows what happens over the next part of the cycle and around the time of egg collection. The study also looks at hormone levels in the blood, including E2 (a form of estrogen), P4 (progesterone), LH (luteinizing hormone), and FSH (follicle-stimulating hormone), which are natural body signals that help control ovulation and egg development.

]]> MV140 for Women with Recurrent Uncomplicated Urinary Tract Infections https://clinicaltrials.eu/trial/mv140-for-women-with-recurrent-uncomplicated-urinary-tract-infections/ Tue, 02 Jun 2026 09:56:40 +0000 https://clinicaltrials.eu/trial/mv140-for-women-with-recurrent-uncomplicated-urinary-tract-infections/ This clinical trial is being done in women with recurrent urinary tract infections, which means repeated infections of the bladder or other parts of the urinary system. The study is testing a mucosal bacterial vaccine called MV140 to see whether it can lower the number of new infections. Some participants will receive MV140 as a spray under the tongue, while others will receive a placebo. During the study, some participants may also use standard infection medicines such as fosfomycin, pivmecillinam, or nitrofurantoin if needed for treatment of an infection episode.

The purpose of the study is to confirm whether MV140 is safe and helpful in reducing repeated urinary tract infections. The trial lasts about 15 months after treatment begins. Over this time, participants are followed for new infection episodes, and study visits are used to check symptoms and general health. The study also looks at side effects and how the treatment affects daily life.

The vaccine used in the study contains inactive forms of common bacteria that can cause urinary tract infections: Klebsiella pneumoniae, Escherichia coli, Enterococcus faecalis, and Proteus vulgaris. These bacteria are not alive in the vaccine. The treatment is given as a small spray under the tongue.

]]> Zenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes https://clinicaltrials.eu/trial/zenagamtide-compared-with-semaglutide-in-adults-with-overweight-or-obesity-and-type-2-diabetes/ Tue, 02 Jun 2026 09:56:38 +0000 https://clinicaltrials.eu/trial/zenagamtide-compared-with-semaglutide-in-adults-with-overweight-or-obesity-and-type-2-diabetes/ This clinical trial is studying type 2 diabetes in people with overweight or obesity. It compares a new medicine called NNC0487-0111, also known as zenagamtide, with semaglutide, which is already used for weight management and diabetes care. The purpose of the study is to see whether NNC0487-0111 helps lower body weight better than semaglutide and to learn more about its safety.

Both medicines are given as a subcutaneous injection, which means an injection under the skin, once a week. People in the study receive one of several dose plans of NNC0487-0111 or semaglutide, and some study groups receive placebo. The study follows changes in body weight, blood sugar, waist size, blood pressure, and other health measures over time. It also looks at side effects, including low blood sugar, which can happen when blood sugar drops too far.

The study is planned to run for a long period, with treatment and follow-up visits spread across the study time. The medicines are given in a pre-filled pen, and the course of the study is designed to compare how the different treatments work and how safe they are in adults with excess body weight and type 2 diabetes.

]]> GB-0895 for Severe Uncontrolled Asthma in Adults and Adolescents https://clinicaltrials.eu/trial/gb-0895-as-add-on-treatment-for-adults-and-adolescents-with-severe-uncontrolled-asthma/ Tue, 02 Jun 2026 09:56:36 +0000 https://clinicaltrials.eu/trial/gb-0895-as-add-on-treatment-for-adults-and-adolescents-with-severe-uncontrolled-asthma/ This clinical trial is studying severe uncontrolled asthma, a form of asthma in which breathing problems and flare-ups are not well controlled with usual treatment. The study is testing GB-0895, given as a subcutaneous injection under the skin, as an extra treatment along with regular asthma care. A placebo is also used for comparison. The purpose of the study is to see whether GB-0895 can help reduce serious asthma flare-ups and whether it is safe to use over time.

Adults and adolescents in the study are assigned by chance to receive either GB-0895 or placebo, and neither the participants nor the study team knows which one is given during the study. Treatment is given over about 52 weeks, with regular study visits during that time. The study looks at how asthma changes over the year, including flare-ups, breathing, asthma symptoms, and daily life with asthma.

Some medical terms used in the study include exacerbations, which means asthma flare-ups that are bad enough to need steroid medicine or a hospital or emergency room visit, and forced expiratory volume in 1 second (FEV1), which is the amount of air that can be blown out in one second. The study also uses systemic corticosteroids, which are steroid medicines that work throughout the body.

]]> Oral Semaglutide in People With Mild Cognitive Impairment or Mild Dementia of the Alzheimer’s Type https://clinicaltrials.eu/trial/oral-semaglutide-in-people-with-mild-cognitive-impairment-or-mild-dementia-of-the-alzheimer-s-type/ Tue, 02 Jun 2026 04:17:48 +0000 https://clinicaltrials.eu/trial/oral-semaglutide-in-people-with-mild-cognitive-impairment-or-mild-dementia-of-the-alzheimer-s-type/ This clinical trial is studying early Alzheimer’s disease, including mild cognitive impairment and mild dementia of the Alzheimer’s type. The treatment being tested is semaglutide, taken as an oral tablet under the brand names Rybelsus 3 mg, Rybelsus 7 mg, and Rybelsus 14 mg. Some people in the study receive placebo tablets instead of the active medicine.

The purpose of the study is to see whether oral semaglutide can help slow worsening of memory, thinking, and daily function in people with early Alzheimer’s disease, and to check its safety. The study is randomised, which means the treatment is assigned by chance, and double-blind, which means neither the participants nor the study team knows who receives semaglutide or placebo during the study. Treatment is taken by mouth over a long period, and the study follows changes over time.

Participants take the study tablets regularly and are seen at planned visits during the trial. These visits are used to monitor health, review how the person is doing, and record any changes in memory, daily activities, or side effects. The study compares how people do over time in the semaglutide and placebo groups.

]]> BI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases https://clinicaltrials.eu/trial/bi-764198-in-adults-and-adolescents-with-proteinuric-kidney-diseases/ Tue, 02 Jun 2026 04:17:47 +0000 https://clinicaltrials.eu/trial/bi-764198-in-adults-and-adolescents-with-proteinuric-kidney-diseases/ This clinical trial is studying proteinuric kidney diseases, which are kidney disorders that cause too much protein to leak into the urine. The study is testing BI 764198, an oral tablet, against a placebo matching BI 764198. The purpose of the study is to see whether BI 764198 is safe and helpful for adults and adolescents with four related kidney conditions: focal segmental glomerulosclerosis (a kidney disease that scars parts of the kidney filter), treatment-resistant primary minimal change disease (a kidney disease that does not improve with usual treatment), Alport syndrome (an inherited kidney disease that can also affect hearing and vision), and treatment-resistant primary membranous nephropathy (a kidney disease caused by damage to the kidney filters). Some participants may already be receiving other kidney medicines such as SGLT2i/CNI, which are drugs often used to protect kidney function and reduce protein loss in the urine.

The study is planned in two groups, and neither the participants nor the study team will know which treatment is given. After starting treatment, the medicine is taken for a period of time and then the study looks at changes in urine protein and kidney function over about 20 weeks. The study is designed to compare BI 764198 with placebo across the different kidney disease groups.

]]> Inclisiran for Preventing Cardiovascular Events in High-Risk Primary Prevention Patients with Atherosclerotic Cardiovascular Disease https://clinicaltrials.eu/trial/inclisiran-for-preventing-cardiovascular-events-in-high-risk-primary-prevention-patients-with-atherosclerotic-cardiovascular-disease/ Tue, 02 Jun 2026 04:17:45 +0000 https://clinicaltrials.eu/trial/inclisiran-for-preventing-cardiovascular-events-in-high-risk-primary-prevention-patients-with-atherosclerotic-cardiovascular-disease/ This study is looking at atherosclerotic cardiovascular disease, a condition in which fatty material builds up in the blood vessels and can lead to heart attack or stroke. The study treatment is inclisiran, given as an injection under the skin, and it is compared with placebo to see whether it can help prevent serious heart and blood vessel events in people at high risk who have not yet had one of these events.

People in the study are assigned by chance to receive either inclisiran or placebo, and neither the participants nor the study team knows which one is given. The study follows participants over time while they receive the injections and are checked regularly for major heart-related problems such as myocardial infarction (heart attack), ischemic stroke (stroke caused by a blocked blood vessel), death from heart disease, or urgent procedures to open blocked heart arteries. The main purpose of the study is to find out whether inclisiran lowers the risk of these serious events better than placebo.

]]> Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia https://clinicaltrials.eu/trial/long-term-safety-study-of-asciminib-in-patients-with-chronic-myelogenous-leukemia-or-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia/ Tue, 02 Jun 2026 04:17:43 +0000 https://clinicaltrials.eu/trial/long-term-safety-study-of-asciminib-in-patients-with-chronic-myelogenous-leukemia-or-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia/ This study is for people with chronic myelogenous leukemia (also called CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is an open-label study, which means the treatment is known to the study team and the participants. The treatment used in the study is asciminib hydrochloride, taken by mouth. The purpose of the study is to check the long-term safety of continuing asciminib after a previous study.

The study follows people who have already completed an earlier asciminib study and are considered by the doctor to still benefit from treatment. Treatment is continued over time, and regular study visits are planned so that health and any side effects can be watched. The study looks at possible adverse events, which are unwanted health problems that happen during treatment, and serious adverse events, which are more severe health problems. In some parts of the study, other tyrosine kinase inhibitors that may have been used in earlier studies include nilotinib, dasatinib, imatinib, and bosutinib.

The study is designed to provide continued access to the same study treatment received before while long-term safety is followed over time.

]]> Cvp Sociedade De Gestao Hospitalar S.A. https://clinicaltrials.eu/site/cvp-sociedade-de-gestao-hospitalar-s-a/ Tue, 02 Jun 2026 04:03:19 +0000 https://clinicaltrials.eu/site/cvp-sociedade-de-gestao-hospitalar-s-a/